Amerise Biosciences (BOM:531681) Notes Receivable: ₹0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531681 Amerise Biosciences Ltd BOM:531681
35 GF Score
Price ₹0.86
View Full Analysis

What is Amerise Biosciences Notes Receivable?

Amerise Biosciences BOM:531681 35 Notes Receivable is ₹0.00 Mil as of Mar. 2026. GuruFocus rates BOM:531681 with a GF Score™ of 35/100.

Amerise Biosciences's Notes Receivable for the quarter that ended in Mar. 2026 was ₹0.00 Mil.

Amerise Biosciences Notes Receivable Related Terms

Amerise Biosciences Notes Receivable Historical Data

* Premium members only.

The historical data trend for Amerise Biosciences's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amerise Biosciences Notes Receivable Chart

Amerise Biosciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Amerise Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:531681
35GF Score
Amerise Biosciences Ltd BOM:531681
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amerise Biosciences Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₹0.00 Mil mean?
Amerise Biosciences (BOM:531681) has a Notes Receivable of ₹0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Amerise Biosciences and its competitors.
Is Amerise Biosciences' Notes Receivable too high?
Amerise Biosciences' current Notes Receivable is ₹0.00 Mil. Overall, Amerise Biosciences has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Amerise Biosciences' Notes Receivable compare to XXI and CCXI?
Amerise Biosciences' Notes Receivable of ₹0.00 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Diversified Financial Services company?
A good Notes Receivable depends on the Diversified Financial Services industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Amerise Biosciences and its competitors. Amerise Biosciences's current Notes Receivable is ₹0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amerise Biosciences stock overvalued right now?
Amerise Biosciences (BOM:531681) has a current Notes Receivable of ₹0.00 Mil. The current Notes Receivable is ₹0.00 Mil. Amerise Biosciences' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Amerise Biosciences (BOM:531681), the current Notes Receivable is ₹0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amerise Biosciences Business Description

Address Navjeevan Press Road, 24, Laxmi Chambers, Opposite Old Gujarat High Court, Ahmedabad, GJ, IND, 380014
Amerise Biosciences Ltd is an Indian company which is not involved in any business activity.
35GF Score

Get the complete analysis for BOM:531681

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹0.86
Price